Travere Therapeutics swings to Q3 net loss of $52.34 million

• Travere Therapeutics swung to a third-quarter 2026 net loss of $52.34 million from a year-earlier profit of $25.71 million.
• Total revenue rose 36% year-over-year to $224.56 million.
• An in-process research and development expense of $113.1 million resulted from closing the Everest Medicines licensing agreement for civorebrutinib.
• Pegtibatinase Phase 3 HARMONY results remain expected in second-half 2027; civorebrutinib U.S. IND submission is planned by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611021601BIZWIRE_USPR_____20261102_BW327521) on November 02, 2026, and is solely responsible for the information contained therein.